181 related articles for article (PubMed ID: 16721548)
1. An evaluation of thymidine phosphorylase as a means of preventing thymidine rescue from the thymidylate synthase inhibitor raltitrexed.
Graham-Cole CL; Thomas HD; Taylor GA; Newell DR; Melton RG; Hesp R; Boddy AV
Cancer Chemother Pharmacol; 2007 Feb; 59(2):197-206. PubMed ID: 16721548
[TBL] [Abstract][Full Text] [Related]
2. Modulation of both endogenous folates and thymidine enhance the therapeutic efficacy of thymidylate synthase inhibitors.
van der Wilt CL; Backus HH; Smid K; Comijn L; Veerman G; Wouters D; Voorn DA; Priest DG; Bunni MA; Mitchell F; Jackman AL; Jansen G; Peters GJ
Cancer Res; 2001 May; 61(9):3675-81. PubMed ID: 11325838
[TBL] [Abstract][Full Text] [Related]
3. Potentiation of the antitumor activity of alpha, alpha, alpha-trifluorothymidine by the co-administration of an inhibitor of thymidine phosphorylase at a suitable molar ratio in vivo.
Emura T; Suzuki N; Fujioka A; Ohshimo H; Fukushima M
Int J Oncol; 2005 Aug; 27(2):449-55. PubMed ID: 16010427
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models.
Ouchi KF; Yanagisawa M; Sekiguchi F; Tanaka Y
Cancer Chemother Pharmacol; 2006 May; 57(5):693-702. PubMed ID: 16362295
[TBL] [Abstract][Full Text] [Related]
5. Serine/threonine protein phosphatase inhibition enhances the effect of thymidylate synthase inhibition.
Sakoff JA; Howitt IJ; Ackland SP; McCluskey A
Cancer Chemother Pharmacol; 2004 Mar; 53(3):225-32. PubMed ID: 14648018
[TBL] [Abstract][Full Text] [Related]
6. Thymidine kinase and thymidine phosphorylase level as the main predictive parameter for sensitivity to TAS-102 in a mouse model.
Emura T; Nakagawa F; Fujioka A; Ohshimo H; Kitazato K
Oncol Rep; 2004 Feb; 11(2):381-7. PubMed ID: 14719072
[TBL] [Abstract][Full Text] [Related]
7. Thymidylate synthase expression in advanced colorectal cancer predicts for response to raltitrexed.
Farrugia DC; Ford HE; Cunningham D; Danenberg KD; Danenberg PV; Brabender J; McVicar AD; Aherne GW; Hardcastle A; McCarthy K; Jackman AL
Clin Cancer Res; 2003 Feb; 9(2):792-801. PubMed ID: 12576452
[TBL] [Abstract][Full Text] [Related]
8. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
[TBL] [Abstract][Full Text] [Related]
9. Balb/c mice as a preclinical model for raltitrexed-induced gastrointestinal toxicity.
Clarke SJ; Farrugia DC; Aherne GW; Pritchard DM; Benstead J; Jackman AL
Clin Cancer Res; 2000 Jan; 6(1):285-96. PubMed ID: 10656460
[TBL] [Abstract][Full Text] [Related]
10. Raltitrexed: optimism and reality.
Wilson KS; Malfair Taylor SC
Expert Opin Drug Metab Toxicol; 2009 Nov; 5(11):1447-54. PubMed ID: 19863453
[TBL] [Abstract][Full Text] [Related]
11. Leucovorin rescue from raltitrexed (tomudex)-induced antiproliferative effects: in vitro cell line and in vivo mouse studies.
Farrugia DC; Aherne GW; Brunton L; Clarke SJ; Jackman AL
Clin Cancer Res; 2000 Sep; 6(9):3646-56. PubMed ID: 10999757
[TBL] [Abstract][Full Text] [Related]
12. Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate, LY231514.
Schultz RM; Patel VF; Worzalla JF; Shih C
Anticancer Res; 1999; 19(1A):437-43. PubMed ID: 10226579
[TBL] [Abstract][Full Text] [Related]
13. The use of raltitrexed (tomudex) in a patient with 5-fluorouracil induced myocardial ischaemia.
Nutting C; Folkes A
Clin Oncol (R Coll Radiol); 1999; 11(1):66. PubMed ID: 10194593
[No Abstract] [Full Text] [Related]
14. Drug resistance in colon cancer.
Gorlick R; Bertino JR
Semin Oncol; 1999 Dec; 26(6):606-11. PubMed ID: 10606253
[TBL] [Abstract][Full Text] [Related]
15. A potential important role for thymidylate synthetase inhibition on antitumor activity of fluoropyrimidine and raltitexed.
Kabeshima Y; Kubota T; Watanabe M; Saikawa Y; Nishibori H; Hasegawa H; Kitajima M
Anticancer Res; 2002; 22(6A):3245-52. PubMed ID: 12530071
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and evaluation of 6-methylene-bridged uracil derivatives. Part 1: discovery of novel orally active inhibitors of human thymidine phosphorylase.
Yano S; Kazuno H; Suzuki N; Emura T; Wierzba K; Yamashita J; Tada Y; Yamada Y; Fukushima M; Asao T
Bioorg Med Chem; 2004 Jul; 12(13):3431-41. PubMed ID: 15186829
[TBL] [Abstract][Full Text] [Related]
17. Thymidine phosphorylase influences [(18)F]fluorothymidine uptake in cancer cells and patients with non-small cell lung cancer.
Lee SJ; Yeo JS; Lee HJ; Lee EJ; Kim SY; Jang SJ; Lee JJ; Ryu JS; Moon DH
Eur J Nucl Med Mol Imaging; 2014 Jul; 41(7):1327-35. PubMed ID: 24562648
[TBL] [Abstract][Full Text] [Related]
18. Thymidine phosphorylase moderates thymidine-dependent rescue after exposure to the thymidylate synthase inhibitor ZD1694 (Tomudex) in vitro.
Patterson AV; Talbot DC; Stratford IJ; Harris AL
Cancer Res; 1998 Jul; 58(13):2737-40. PubMed ID: 9661884
[TBL] [Abstract][Full Text] [Related]
19. Modulation of RTX cytotoxicity by thymidine and dipyridamole in vitro: implications for chemotherapy.
Lehman NL; Danenberg PV
Cancer Chemother Pharmacol; 2000; 45(2):142-8. PubMed ID: 10663629
[TBL] [Abstract][Full Text] [Related]
20. Targeting thymidylate synthase in colorectal cancer: critical re-evaluation and emerging therapeutic role of raltitrexed.
Avallone A; Di Gennaro E; Silvestro L; Iaffaioli VR; Budillon A
Expert Opin Drug Saf; 2014 Jan; 13(1):113-29. PubMed ID: 24093908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]